Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs
- 1 November 1999
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 62 (1-2) , 187-192
- https://doi.org/10.1016/s0168-3659(99)00037-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of ratsEuropean Journal of Pharmaceutical Sciences, 1998
- Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy*Clinical Pharmacology & Therapeutics, 1997
- The disposition of valproyl glycinamide and valproyl glycine in rats.Pharmaceutical Research, 1997
- Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of ValpromidePharmaceutical Research, 1996
- Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and GlycinePharmaceutical Research, 1995
- Severe Hepatotoxicity During Valproate Therapy: An Update and Report of Eight New FatalitiesEpilepsia, 1994
- Can we develop improved derivatives of valproic acid?Pharmacy World & Science, 1994
- Valproic Acid‐Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible MechanismsBasic & Clinical Pharmacology & Toxicology, 1991
- Clinical Pharmacology of ValpromideClinical Pharmacokinetics, 1991
- Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic ActivityPharmaceutical Research, 1989